dexrazoxane

Contraindicated in:

Any other type of chemotherapy except other anthracyclines (doxorubicin-like agents);
Hepatic impairment (for treatment of extravasation only);
OB: Pregnancy;
Lactation: Lactation.

Use Cautiously in:

Renal impairment (CCr <40 mL/min) (↓ dose);
Rep: Women of reproductive potential and men with female partners of reproductive potential;
Pedi: Safety and effectiveness not established in children.

Adv. Reactions/Side Effects ⬆ ⬇

GU: ↓fertility (males)

Hemat: leukopenia, neutropenia, thrombocytopenia

Local: pain at injection site

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA), MALIGNANCY

Interactions ⬆ ⬇

Drug-drug:

Myelosuppression may be ↑ by antineoplastics or radiation therapy.
Antitumor effects of concurrent combination chemotherapy with fluorouracil and cyclophosphamide may be ↓ by dexrazoxane.

Availability ⬆ ⬇

(Generic available)

Lyophilized powder for injection: 250 mg/vial; 500 mg/vial

Route/Dosage ⬆ ⬇

Cardioprotective

IV (Adults ): 10 mg of dexrazoxane/1 mg doxorubicin.

Renal Impairment

IV (Adults ): CCr <40 mL/min:↓ dose by 50%.

Extravasation Treatment

IV (Adults ): 1000 mg/m² (maximum 2000 mg) given on days 1 and 2, and followed by a dose of 500 mg/m² (maximum 1000 mg) on day 3.

Renal Impairment

IV (Adults ): CCr <40 mL/min:↓ dose by 50%.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Acts as an intracellular chelating agent.

Therapeutic effects:

Diminishes the cardiotoxic effects of doxorubicin.
Decreased damage from extravasation of anthracyclines.

Classifications ⬆ ⬇

Therapeutic Classification: cardioprotective agents

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Some metabolism occurs; 42% eliminated in urine.

Half-Life: 2.1–2.5 hr.

Canadian Brand Names ⬆ ⬇

Time/Action Profile ⬆ ⬇

(cardioprotective effect)

ROUTE	ONSET	PEAK	DURATION
IV	rapid	unknown	unknown

Patient/Family Teaching ⬆ ⬇

Explain the purpose of the medication to the patient.
Emphasize the need for continued monitoring of cardiac function.
Rep: Dexrazoxane may cause fetal harm. Advise females of reproductive potential to use highly effective contraception during and for 6 mo after last dose of dexrazoxane and to avoid breastfeeding during and for 2 wk after last dose. Advise males with female partners of reproductive potential to use highly effective contraception during and for 3 mo after last dose. Advise patient to notify health care professional immediately if pregnancy is suspected. May impair fertility in males.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

0013- Pharmacia and Upjohn Company LLC
- 0013-8717- Zinecard
  - 0013-8717-62- 1 VIAL, SINGLE-DOSE in 1 CARTON (0013-8717-62) > 25 mL in 1 VIAL, SINGLE-DOSE

0013- Pharmacia and Upjohn Company LLC
- 0013-8727- Zinecard
  - 0013-8727-89- 1 VIAL, SINGLE-DOSE in 1 CARTON (0013-8727-89) > 50 mL in 1 VIAL, SINGLE-DOSE

0143- West-Ward Pharmaceuticals Corp
- 0143-9247- Dexrazoxane
  - 0143-9247-01- 1 VIAL in 1 BOX (0143-9247-01) > 25 mL in 1 VIAL

0143- West-Ward Pharmaceuticals Corp
- 0143-9248- Dexrazoxane
  - 0143-9248-01- 1 VIAL in 1 BOX (0143-9248-01) > 50 mL in 1 VIAL

47781- Alvogen Inc.
- 47781-578- Dexrazoxane
  - 47781-578-07- 1 VIAL, SINGLE-DOSE in 1 CARTON (47781-578-07) > 50 mL in 1 VIAL, SINGLE-DOSE

51991- Breckenridge Pharmaceutical, Inc.
- 51991-942- Dexrazoxane
  - 51991-942-98- 1 VIAL, SINGLE-DOSE in 1 CARTON (51991-942-98) > 50 mL in 1 VIAL, SINGLE-DOSE

66220- Cumberland Pharmaceuticals Inc.
- 66220-110- Totect
  - 66220-110-01- 1 VIAL, SINGLE-USE in 1 CARTON (66220-110-01) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-USE

67457- Mylan Institutional LLC
- 67457-207- Dexrazoxane Hydrochloride
  - 67457-207-25- 1 KIT in 1 PACKAGE (67457-207-25) * 25 mL in 1 VIAL (67457-205-25) * 25 mL in 1 VIAL, SINGLE-DOSE (67457-204-25)

67457- Mylan Institutional LLC
- 67457-208- Dexrazoxane Hydrochloride
  - 67457-208-50- 1 KIT in 1 PACKAGE (67457-208-50) * 50 mL in 1 VIAL (67457-205-50) * 50 mL in 1 VIAL, SINGLE-DOSE (67457-209-50)

68083- Gland Pharma Limited
- 68083-195- Dexrazoxane
  - 68083-195-01- 1 VIAL in 1 CARTON (68083-195-01) > 50 mL in 1 VIAL

72266- Fosun Pharma USA Inc.
- 72266-101- Dexrazoxane
  - 72266-101-01- 1 VIAL in 1 CARTON (72266-101-01) > 50 mL in 1 VIAL

76310- Clinigen Healthcare Ltd
- 76310-002- Cardioxane
  - 76310-002-01- 1 VIAL, GLASS in 1 CARTON (76310-002-01) > 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, GLASS

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇